MetaCap

ImmunityBio (IBRX) vs Immunovant (IMVT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ImmunityBio (IBRX) has outperformed Immunovant (IMVT) over the past year, gaining 189.4% versus a gain of 40.6%. Over five years, IMVT leads with a +308.9% price change compared with -7.4% for IBRX. Immunovant is the larger company by market cap ($6.57 billion vs $6.40 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IBRX+189.42%IMVT+40.64%
+478%+225%-28%
Nov 21, 20251 yearNov 20, 2026
IBRX-6.38%IMVT+286.50%
+466%+180%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IBRX versus IMVT key metrics
MetricIBRXIMVT
Share price$6.02$31.77
Market cap$6.40B$6.57B
1-day change-8.37%-2.31%
YTD return+204.04%+24.98%
1-year return+189.42%+40.64%
5-year return-7.38%+308.88%
EPS (TTM)$-1.06$-2.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$113.29M—
Revenue growth (YoY)+668.31%—
Net income (latest FY)$-351.40M$-505.61M
Gross margin99.34%—
Operating margin-226.00%—
Net margin-310.18%—
52-week high$12.43$45.42
52-week low$1.95$21.93
Distance from 52-week high-51.57%-30.05%
Analyst consensusstrong_buybuy
Avg. price target upside+136.71%+53.07%
Average volume12.97M1.42M
Shares outstanding1.06B206.95M
Employees684315
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IBRX has outperformed IMVT by 148.8 percentage points over the past year.

About ImmunityBio

IBRX stock →

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees

About Immunovant

IMVT stock →

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees

IBRX vs IMVT FAQ

Which is bigger, ImmunityBio or Immunovant?

Immunovant (IMVT) is larger, with a market capitalization of $6.57B compared with $6.40B for ImmunityBio (IBRX).

Which stock has performed better over the past year, IBRX or IMVT?

IBRX returned +189.42% over the past 12 months, compared with +40.64% for IMVT (price return, excluding dividends). Past performance does not predict future results.

Are ImmunityBio and Immunovant in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons